|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 66.74 USD | -0.51% |
|
-0.76% | +7.05% |
| May. 16 | Axonics Implant Approved in Australia to Treat Overactive Bladders | MT |
| May. 16 | Axonics, Inc. Receives Regulatory Approval for Recharge-Free SNM System in Australia | CI |
Axonics, Inc. announced that it has received regulatory approval from the Therapeutic Goods Administration (TGA) for marketing the Axonics F15?? recharge-free sacral neuromodulation (SNM) system in Australia to treat adults with overactive bladder. Axonics commenced SNM commercial activities in Australia in March 2023.
In Australia, in addition to its SNM products, Axonics markets Bulkamid®, the company?s unique hydrogel indicated for female stress urinary incontinence.
| 1st Jan change | Capi. | |
|---|---|---|
| +7.05% | 3.42B | |
| +13.17% | 130B | |
| -8.74% | 10.99B | |
| -5.82% | 8.35B | |
| +41.75% | 5.67B | |
| -26.78% | 4.72B | |
| -11.81% | 2.76B | |
| -14.30% | 1.92B | |
| -30.16% | 1.68B | |
| -9.05% | 1.15B |
AXONICS, INC. 
